Figure 2. Risk of Hemorrhagic Stroke.

Relative risk (RR) of hemorrhagic stroke with more intensive vs less intensive low-density lipoprotein cholesterol–lowering statin-based therapies among patients with stroke. Different sizes of markers indicate the different weights used for pooled analysis. FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk; HPS, Heart Protection Study; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; J-STARS, Japan Statin Treatment Against Recurrent Stroke; PCSK9, proprotein convertase subtilisin/kexin type 9; PODCAST, Prevention of Decline in Cognition after Stroke Trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; and TST, Treat Stroke to Target.